Abstinence · cannabis dependence
Δ9‐Tetrahydrocannabinol preparation showed no clear difference in participants abstinent at end of treatment compared with placebo (moderate certainty).
1 finding from 1 review
Participants with at least some Side Effects · cannabis dependence
Δ9‐Tetrahydrocannabinol preparation showed no clear difference in participants experiencing adverse effects compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · cannabis dependence
Δ9‐Tetrahydrocannabinol preparation showed no clear difference in participants withdrawn due to adverse effects compared with placebo (low certainty).
1 finding from 1 review
Completion of scheduled treatment · cannabis dependence
Δ9‐Tetrahydrocannabinol preparation showed no clear difference in completion of scheduled treatment compared with placebo (low certainty).
1 finding from 1 review
Adverse events · patients with requirement of prophylaxis to avoid allergic and febrile non‐haemolytic transfusion reactions
Acetaminophen plus Diphenhydrammine led to lower adverse events compared with placebo (Unit of randomisation: transfusion); GRADE not reported.
1 finding from 1 review
Fever · patients with requirement of prophylaxis to avoid allergic and febrile non‐haemolytic transfusion reactions
Acetaminophen plus Diphenhydrammine showed no clear difference in fever ‐ Per protocol analysis compared with placebo (Unit of randomisation: transfusion) (low certainty).
1 finding from 1 review
Anaphylatic reactions ‐ not reported · patients with requirement of prophylaxis to avoid allergic and febrile non‐haemolytic transfusion reactions
Acetaminophen plus Diphenhydrammine led to lower anaphylatic reactions ‐ not reported compared with placebo (Unit of randomisation: transfusion); GRADE not reported.
1 finding from 1 review
Hives ‐ Per protocol analysis · patients with requirement of prophylaxis to avoid allergic and febrile non‐haemolytic transfusion reactions
Acetaminophen plus Diphenhydrammine showed no clear difference in hives ‐ Per protocol analysis compared with placebo (Unit of randomisation: transfusion) (low certainty).
1 finding from 1 review
Death ‐ not reported · patients with requirement of prophylaxis to avoid allergic and febrile non‐haemolytic transfusion reactions
Acetaminophen plus Diphenhydrammine led to lower death ‐ not reported compared with placebo (Unit of randomisation: transfusion); GRADE not reported.
1 finding from 1 review
Mean GI symptom scores (IBDQ‐B) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acute and late GI toxicity (grade 2+) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
Summary of findings: Aminosalicylates probably leads to higher acute and late GI toxicity (grade 2+) compared with placebo (moderate certainty).
1 finding from 1 review
Diarrhoea (grade 2+) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cannabis use · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Mental state: PANSS total (high = bad) ‐ medium term ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Global state: relapse ‐ medium term ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
General functioning ‐ no clinically important change in general functioning · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects: measured adverse events ‐ medium term ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Leaving the study early ‐ medium term ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Satisfaction with treatment ‐ medium term ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review